Next |
home / stock / scyx / scyx message board
Subject | By | Source | When |
---|---|---|---|
Gap fills in the 1.8's, golden cross around | BooDog | investorshub | 04/24/2023 3:12:38 PM |
Buy orders getting triggered. Just watch | BooDog | investorshub | 04/12/2023 4:40:04 PM |
Placed a buy order at 3.39 and took | duderaja | investorshub | 04/04/2023 2:08:55 PM |
Check this out: | duderaja | investorshub | 04/03/2023 7:28:52 PM |
$SCYX: Hey, THANKS, Capt. S-L!!! (& best of | Invest-in-America | investorshub | 04/03/2023 6:41:25 PM |
You are doing great my friend! Sweet find. | subslover | investorshub | 04/03/2023 6:37:31 PM |
$SCYX: THANKS, Capt. S-L!!! | Invest-in-America | investorshub | 04/03/2023 2:28:29 PM |
NEWS SCYNEXIS Reports Fourth Quarter and Full Year 2022 | subslover | investorshub | 04/03/2023 1:04:04 PM |
More upgrades coming. | duderaja | investorshub | 03/31/2023 10:36:48 AM |
znewcar1: $SCYX 76% v52,1M c2.94 f32,656M H2.97 RL1.6 off 30 day | znewcar1 | investorshangout | 03/30/2023 8:47:44 PM |
SCYNEXIS, Maxim Raises Price Target To $10, GSK | BooDog | investorshub | 03/30/2023 8:00:05 PM |
GSK Bets On Scynexis' FDA-Approved Antifungal Drug For | BooDog | investorshub | 03/30/2023 5:49:30 PM |
$SCYX: Well, at least I'm BANKING over here!! | Invest-in-America | investorshub | 03/30/2023 2:53:44 PM |
GSK and SCYNEXIS Announce an Exclusive Agreement to | BooDog | investorshub | 03/30/2023 12:41:45 PM |
FUNNY!!! (I was just being my silly, childish, | Invest-in-America | investorshub | 03/30/2023 12:41:32 PM |
Heard that your knee deep in fungi lol | subslover | investorshub | 03/30/2023 12:33:31 PM |
10-K next week probably. Nice reset. | BooDog | investorshub | 03/23/2023 2:54:45 PM |
Q4 and annual earnings should be due within | murocman | investorshub | 03/23/2023 1:56:27 PM |
I like this play. | enthalpy | investorshub | 03/23/2023 1:11:57 PM |
znewcar1: $SCYX 28% v14,5M c2.00 f32,6M H2.28 ML1.15 | znewcar1 | investorshangout | 03/22/2023 10:41:08 PM |
News, Short Squeeze, Breakout and More Instantly...
SCY-247’s IND-enabling activities continue to progress, with initiation of Phase I anticipated in the second half of 2024 Clinical study reports for the FURI, CARES and NATURE trials in refractory invasive fungal infections remain on track for delivery to GSK in mid 2024, which would...
In vivo data demonstrated efficacy of SCY-247 in mouse model of invasive candidiasis caused by Candida glabrata SCY-247 showed in vitro activity ...
In vivo data demonstrated efficacy of SCY-247 in mouse model of invasive candidiasis caused by Candida glabrata SCY-247 showed in vitro activity against a broad range of pathogenic fungi, including azole-resistant strains of Candida and Aspergillus species JERSEY C...